Products for Research Use Only
RegisterLogin

LDN-212854

CAT: 0804-HY-15897-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15897-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM) . LDN-212854 also inhibits ALK1 (IC50: 2.40 nM) . LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) [1][2].
CAS Number
1432597-26-6
UNSPSC
12352005
Hazard Statement
H301
Target
TGF-β Receptor
Type
Reference compound
Related Pathways
TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LDN-212854.html
Concentration
10mM
Purity
99.70
Solubility
DMSO : ≥ 30 mg/mL
Smiles
C12=C(C3=C4N=CC(C5=CC=C(N6CCNCC6)C=C5)=CN4N=C3)C=CC=C1N=CC=C2
Molecular Formula
C25H22N6
Molecular Weight
406.48
Precautions
H301
References & Citations
[1]Mohedas AH, et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013;8 (6) :1291-302.|[2]Han Chen, et al. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma. Mol Oncol. 2021 Aug;15 (8) :2203-2218.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ALK1; ALK2; ALK3; ALK4; ALK5

Related Products

CatalogName
HY-136358LDN-211904
HY-12989-01LDN-91946
HY-12741-01LDN-212320
HY-13455-01LDN-192960
HY-120744LDN-193665
HY-16693-01LDN-27219
HY-135002LDN-209929
HY-16712-01LDN-214117
HY-18637-01LDN-57444
HY-110260-01LDN-193188

Alternative Products

CatalogName
B3687-50LDN-212854
JJD41480-01Ldn 212854 trihydrochloride
A12821-25LDN-212854 25mg
A12821-100LDN-212854 100mg

Popular Products